Two reports describe technology advances aimed at overcoming key barriers to CAR‑T efficacy in solid tumors. Researchers unveiled ultra‑sensitive CAR T cells engineered to detect low‑density antigens and preclinical/early clinical data from new cell therapy modalities that address tumor heterogeneity and the suppressive microenvironment. Both accounts emphasize engineering of antigen sensitivity, trafficking, and safety switches to broaden CAR‑T applicability beyond hematologic malignancies. Translation risks remain high, but these designs signal an intensified push to make cell therapy work in solid cancers.